Fragment-based lead discovery to identify novel inhibitors that target the ATP binding site of pyruvate dehydrogenase kinases

Bioorganic & Medicinal Chemistry
2021.0

Abstract

A fragment-based lead discovery approach was applied to Pyruvate Dehydrogenase Kinases (PDHKs) to discover inhibitors against the ATP binding site with novel chemotypes. X-ray fragment screening toward PDHK4 provided a fragment hit 1 with a characteristic interaction in a deep pocket of the ATP binding site. While known inhibitors utilize several water molecules in a deep pocket to form water-mediated hydrogen bond interactions, the fragment hit binds deeper in the pocket with a hydrophobic group. Displacement of a remaining water molecule in the pocket led to the identification of lead compound 7 with a notable improvement in inhibition potency. This lead compound possessed high ligand efficiency (LE) and showed decent selectivity profile. Two additional lead compounds 10 and 13 with new scaffolds with tricyclic and bicyclic cores were generated by merging structural information of another fragment hit 2. The characteristic interaction of these novel inhibitors in a deep pocket provides new structural insights about PDHKs ATP binding site and opens a novel direction for the development of PDHKs inhibitors.

Knowledge Graph

Similar Paper

Fragment-based lead discovery to identify novel inhibitors that target the ATP binding site of pyruvate dehydrogenase kinases
Bioorganic & Medicinal Chemistry 2021.0
Aminoindazole PDK1 Inhibitors: A Case Study in Fragment-Based Drug Discovery
ACS Medicinal Chemistry Letters 2010.0
Design and Synthesis of Novel Lactate Dehydrogenase A Inhibitors by Fragment-Based Lead Generation
Journal of Medicinal Chemistry 2012.0
Application of Fragment Screening by X-ray Crystallography to the Discovery of Aminopyridines as Inhibitors of β-Secretase
Journal of Medicinal Chemistry 2007.0
Fragment-based discovery of potent ERK2 pyrrolopyrazine inhibitors
Bioorganic & Medicinal Chemistry Letters 2015.0
Identification of N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design
Journal of Medicinal Chemistry 2008.0
Fragment Growing and Linking Lead to Novel Nanomolar Lactate Dehydrogenase Inhibitors
Journal of Medicinal Chemistry 2013.0
A fragment-based approach leading to the discovery of a novel binding site and the selective CK2 inhibitor CAM4066
Bioorganic & Medicinal Chemistry 2017.0
Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds
Journal of Medicinal Chemistry 2021.0
Fragment-Based Discovery and Optimization of Enzyme Inhibitors by Docking of Commercial Chemical Space
Journal of Medicinal Chemistry 2017.0